Chapter 01 · Live audit · read 2026-08-20
The content is working. Almost nobody is being shown it.
Conexeu’s best LinkedIn post earned 109.9 engagements per thousand followers. Galderma’s best earned 1.1. The engagement rate is not the problem — the audience is 746 people, two of the four named channels do not exist, and the last eight days are silent.
The accounts
Two channels exist, two do not, and the two that exist are the wrong size
conexeu.com links to exactly two social properties: a LinkedIn company page and an Instagram account. There is no Facebook page and no TikTok account. The Facebook gap is an oversight worth closing. The TikTok gap is the same call every large brand in this category has made, and Chapter 06 sets out why it is the defensible one for now.
- 746linkedin.com/company/conexeu-sciences-inc — the only channel with an investor and clinician audience.
- 695@conexeusciences — following 13 accounts. The account is broadcasting, not participating.
- TikTok
- NoneNo account — and no brand in the category has one. Where patients research, and where a regulated product is hardest to promote lawfully.
- NoneNo page. Lowest priority, but it is the surface Meta ad delivery and Google brand results both reference.
Instagram: followers, Conexeu against the aesthetics field
Allergan Aesthetics
150,000
AbbVie. Partner-creator content most weeks.
Aesthetics by Galderma
76,400
Follows 8 accounts. Pure broadcast, and it works.
Evolus
59,000
Jeuveau. Consumer-facing tone.
Merz Aesthetics US
40,900
Radiesse, Xeomin, Neocutis under one handle.
Sculptra by Galderma
40,000
A single product with its own 40k account.
Revanesse
31,000
Prollenium’s HA line.
Renuva
13,600
Follows 4,528 accounts — deliberate follow-back growth.
Prollenium
12,000
Corporate handle.
Conexeu Sciences
695
Follows 13. Twelve posts visible.
Read off the live profiles on 2026-08-20. Follower count is not the goal — it is the ceiling on how many people any single post can reach organically.
LinkedIn: followers, Conexeu against the regenerative-tissue field
Galderma
558,848
Category owner. Corporate, global, all indications.
Integra LifeSciences
100,252
Dermal regeneration template. The incumbent.
Organogenesis
24,138
Advanced wound care and surgical.
Aroa Biosurgery
4,565
Ovine forestomach ECM — the nearest analog.
AROA ECM (showcase)
1,315
Product showcase page, separately followed.
Conexeu Sciences
746
Six posts since May 2026.
Read off the live pages on 2026-08-20. Aroa Biosurgery is the closest structural analog to CXU™ in this list and carries 6× Conexeu’s audience on a comparable stage of commercialisation.
Every post, read live
The six LinkedIn posts, ranked by what they actually earned
Sort the table by the last column and the pattern is immediate: video with a named human in it beats text with a link, every time, by roughly 3×. The two worst performers are both third-party announcements with no face and no motion.
| Account | What it was | Format | Audience | Engagements | Per 1k followers |
|---|---|---|---|---|---|
| GaldermaCorporate page | FDA approval of Sculptra for cheek wrinkles — a regulatory milestone posted flat | Image + link | 558,848 | 637 | 1.1 |
| MiMedxCorporate page | Exclusive US distribution agreement with RegenLab for RegenKit Wound Gel | Text + link | — | 236 | — |
| Flemming Ornskov, MDGalderma chair, personal | “The menopause symposium at AMWC this morning was a full room, with a clear focus on evidence” — 4,300-woman survey, told in the first person | Text — personal | — | 225 | — |
| Luba Perry, PhDWyss Institute, personal | “I’m thrilled to introduce ReConstruct: vascularized tissues for breast reconstruction” — a scientist launching her own programme | Video — personal | — | 190 | — |
| Conexeu Sciences Inc.Us — corporate page | “A defining moment. A new chapter.” Nasdaq unveil film | Video — native | 746 | 82 | 109.9 |
| Conexeu Sciences Inc.Us — corporate page | CEO Miles Harrison on Stocks to Watch — the GLP-1 tissue-depletion thesis | Video — off-platform link | 746 | 33 | 44.2 |
| Aroa BiosurgeryRing-1 analog, corporate | “Minimal complications. Maximum confidence.” — three clinical bullets and a link | Text + link | 4,565 | 32 | 7.0 |
| Conexeu Sciences Inc.Us — corporate page | B.R.E.A.S.T.™ preclinical programme opens at the Wake Forest Institute for Regenerative Medicine | Text + link | 746 | 30 | 40.2 |
| Conexeu Sciences Inc.Us — corporate page | “Conexeu Sciences Inc. has a new look, but our mission remains the same” | Text only | 746 | 28 | 37.5 |
| Conexeu Sciences Inc.Us — corporate page | CSO Dr Claudia Chavez-Munoz on Progress, Potential, and Possibilities | Video — off-platform link | 746 | 23 | 30.8 |
| Conexeu Sciences Inc.Us — corporate page | Three new directors, a Chief Commercial Officer and an advisory-board appointment | Text + link | 746 | 11 | 14.7 |
Conexeu’s own posts plus four category reference points, read off the live posts on 2026-08-20. ‘Engagements’ is reactions plus comments where both were visible; reactions alone where the comment count was not rendered. Filter and sort the table. Rows without an audience figure are accounts whose follower count is not public.
Conexeu is beating Galderma 100× on engagement rate and losing to it 8× on absolute engagement. Both facts matter, and only one of them is fixable with content.
109.9 engagements per thousand followers against Galderma’s 1.1 is what a small, invested audience looks like — founders, employees, early investors, the Wake Forest and adMare networks. That audience is real and it is responding.
But 82 engagements is 82 engagements. Healthcare, pharma and biotech average roughly 3.3% engagement on LinkedIn; Conexeu’s median post is at 3.9%. The account is already at benchmark. Every further gain has to come from reach, not from rate — which means formats that travel past the follower graph, and people posting from their own profiles.
The Instagram feed, as it reads today
Twelve posts visible on @conexeusciences: two carousels in August and July, a repost of a podcast appearance, a “Regenerate… don’t replace” static frame, the Nasdaq listing, and a run of brand-film clips. The mix is right in principle — carousel, video, static — and wrong in practice, because the cadence collapses.
| Posted | Format | Gap since previous | Read |
|---|---|---|---|
| 12 Aug 2026 | Carousel | 34 days | The longest silence in the feed sits immediately before the most recent post. Eight further days of silence follow it, to today. |
| 9 Jul 2026 | Carousel | 1 day | Two carousels back to back, then nothing. |
| 8 Jul 2026 | Clip (repost) | 1 day | A repost of Ira S. Pastor’s podcast. Borrowed reach — the right instinct, executed once. |
| 7 Jul 2026 | Static frame | 12 days | “REGENERATE… DON’T REPLACE — the future of breast reconstruction beyond implants.” The strongest line in the whole feed, on the weakest format. |
| 25 Jun 2026 | Static frame | 7 days | |
| 18 Jun 2026 | Clip | 2 days | “Architecting Bioregeneration™” brand film. |
| 16 Jun 2026 | Clip | 5 days | Nasdaq listing. |
| 11 Jun 2026 | Clip | 20 days | Brand film again. |
| 22 May 2026 | Carousel | 1 day | |
| 21 May 2026 | Static frame | 1 day | |
| 20 May 2026 | Clip | 6 days | |
| 14 May 2026 | Clip | — | Oldest post visible in the grid. |
Read off the live grid on 2026-08-20. Instagram’s ranking treats a dormant account as a low-confidence account: gaps of this size mean each return post is re-tested against a cold audience rather than building on the last one.
The one line worth building a quarter around
“Regenerate, don’t replace.” That is the whole category argument in three words, it is compliant, it is unclaimed, and it is currently sitting on a static JPEG posted once in July.
It should be the spine of the mechanism film, slide one of the proof carousel, and the on-screen hook of the first macro material film.
Where the traffic lands
Three site defects that waste every click social sends
Social traffic is only worth what the landing surface converts. Four findings from the conexeu.com audit change what social should link to, today, before any new content ships.
- No canonical tag and no JSON-LD anywhere on the marketing site. Not a missing Person node — there is no Organization or Corporation node at all on conexeu.com. Social profiles are the strongest
sameAssignals an entity graph can carry, and right now they point at a page that does not claim an identity. Chapter 07 handles this. - All twelve public pages carry the same meta description. Google discards duplicates, so the effect is identical to having none. Any post that links to a vertical page is sending traffic to a page with no distinct promise in search.
- A page titled “IN WORK — Aesthetics | CXU” is published and publicly reachable at
/platform/in-work---aesthetics-cxu. Aesthetics is the market this plan is built on. Do not link a single post to the aesthetics vertical until that URL is resolved. - Every vertical template page renders seven
h1elements —/sciencerenders thirteen. Both Google and every answer engine read the heading tree to decide what a page is about. Seven competing h1s means the page claims nothing.
These four are from the reconciled conexeu.com website-update plan dated 16 August 2026, already staged on conexeu-bioregeneration.webflow.io. Production is unchanged as of this document. The social calendar in Chapter 08 assumes the staged fixes publish in phase one.